Journal Options Hepatitis
Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
Featured Expert Commentary
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
Clinical Director of Research, Scripps Translational Science Institute
The Scripps Clinic
La Jolla, California
Recent Articles
Telaprevir for retreatment of HCV infection.
Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011;364:2417-2428. Capsule Summary | Expert Commentary | Abstract | Slides
Response-guided telaprevir combination treatment for hepatitis C virus infection.
Sherman KE, Flamm SL, Afdhal NH, et al. N Engl J Med. 2011;365:1014-1024. Capsule Summary | Expert Commentary | Abstract | Slides
Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F, McCone J Jr, Bacon BR, et al. N Engl J Med. 2011;364:1195-1206. Capsule Summary | Expert Commentary | Abstract | Slides
Telaprevir for previously untreated chronic hepatitis C virus infection.
Jacobson IM, McHutchison JG, Dusheiko G, et al. N Engl J Med. 2011;364:2405-2416. Capsule Summary | Expert Commentary | Abstract | Slides
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Hepatology. 2011;54:20-27. Capsule Summary | Expert Commentary | Abstract | Slides
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Foster GR, Hézode C, Bronowicki JP, et al. Gastroenterology. 2011;141:881-889. Capsule Summary | Expert Commentary | Abstract | Slides
The cost-effectiveness of screening for chronic hepatitis B infection in the United States.
Eckman MH, Kaiser TE, Sherman KE. Clin Infect Dis. 2011;52:1294-1306. Capsule Summary | Expert Commentary | Abstract | Slides
Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR, Gordon SC, Lawitz E, et al. N Engl J Med. 2011;364:1207-1217. Capsule Summary | Expert Commentary | Abstract | Slides
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
Williams CD, Stengel J, Asike MI, et al. Gastroenterology. 2011;140:124-131. Capsule Summary | Expert Commentary | Abstract | Slides
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.
Bajaj JS, Heuman DM, Wade JB, et al. Gastroenterology. 2011;140:478-487. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
Volume 5, Issue 1
Collection
Journal Options Hepatitis – Volume 5, Issue 1
Program Director: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
  
- Scott Cotler, MD
- Stuart C. Gordon, MD
- Donald M. Jensen, MD
|
 
- Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
- Brian L. Pearlman, MD, FACP
- Paul J. Pockros, MD
|
 
- Mitchell L. Shiffman, MD
- John M. Vierling, MD, FACP
|
Volume 4, Issue 3
Collection
Hepatitis Journal Options – Volume 4, Issue 3
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, FACP
  
- Hari S. Conjeevaram, MD, MSc
- Adrian M. Di Bisceglie, MD, FACP
- Eric Lawitz, MD
|
  
- Kevin Mullen, MD
- Brent A. Neuschwander-Tetri, MD
- Robert P. Perrillo, MD
|
 
- Richard K. Sterling, MD, MSc, FACP, FACG
- Tram T. Tran, MD
|
|